The award follows the execution of a 2019 contract, valued at $20 million, to advance the development of vaccines against Ebola, Sudan, and Marburg viruses through phase II trials. Also in 2019, Sabin exclusively licensed technology for the vaccine candidate from GlaxoSmithKline, based on the ChAd3 adenoviral vector vaccine platform.
The new funding will enable Sabin and ReiThera to advance the investigational Ebola and Marburg vaccines through good manufacturing practice (GMP) manufacturing and release of ChAd3-MARV and ChAd3-SUDV phase II clinical materials and conduct pilot efficacy and immunogenicity studies. Under terms of the agreement, nonclinical and phase II clinical trials in the U.S. and Africa may be supported by an additional $87.5 million in funding from the BARDA contract.
Copyright © 2020 scienceboard.net